Judgment of the General Court of 12 December 2018 — Krka v Commission

(Case T-684/14) (1)

((Competition - Agreements, decisions and concerted practices - Market for perindopril, a medicinal product intended for the treatment of cardiovascular diseases, in its originator and generic versions - Decision finding an infringement of Article 101 TFEU - Patent dispute settlement agreement - Licensing agreement - Technology acquisition agreement - Restriction of competition by object - Restriction of competition by effect - Balance between competition law and patent law))

(2019/C 82/30)

Language of the case: English

Parties

Applicant: Krka Tovarna Zdravil d.d. (Novo Mesto, Slovenia) (represented by T. Ilešič and M. Kocmut, lawyers)

Defendant: European Commission (represented by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, assisted by D. Bailey, Barrister)

Re:

Application under Article 263 TFEU for partial annulment of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU [Case AT.39612 — Perindopril (Servier)] in so far as it concerns the applicant.

Operative part of the judgment

The Court:

1.	Annuls Article 4 of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU (Case AT.39612 — Perindopril (Servier)) in so far as it finds that Krka Tovarna Zdravil d.d. participated in the agreements referred to in that article;

2.	Annuls Article 7(4)(a) of Decision C(2014) 4955 final;

3.	Annuls Articles 8 and 9 of Decision C(2014) 4955 final, in so far as they concern Krka Tovarna Zdravil;

4.	Orders the Commission to pay the costs.

---

(1)  OJ C 431, 1.12.2014.